High-Density Lipoprotein and Long-Term Incidence and Progression of Aortic Valve Calcification: The Multi-Ethnic Study of Atherosclerosis.


Journal

Arteriosclerosis, thrombosis, and vascular biology
ISSN: 1524-4636
Titre abrégé: Arterioscler Thromb Vasc Biol
Pays: United States
ID NLM: 9505803

Informations de publication

Date de publication:
10 2022
Historique:
pubmed: 19 8 2022
medline: 24 9 2022
entrez: 18 8 2022
Statut: ppublish

Résumé

Aortic valve calcification (AVC) shares pathological features with atherosclerosis. Lipoprotein components have been detected in aortic valve tissue, including HDL (high-density lipoprotein). HDL measures have inverse associations with cardiovascular disease, but relationships with long-term AVC progression are unclear. We investigated associations of HDL cholesterol, HDL-particle number and size, apoC3-defined HDL subtypes, and, secondarily, CETP (cholesteryl ester transfer protein) mass and activity, with long-term incidence and progression of AVC. We used linear mixed-effects models to evaluate the associations of baseline HDL indices with AVC. AVC was quantified by Agatston scoring of up to 3 serial computed tomography scans over a median of 8.9 (maximum 11.2) years of follow-up in the Multi-Ethnic Study of Atherosclerosis (n=6784). After adjustment, higher concentrations of HDL-C (high-density lipoprotein cholesterol), HDL-P (HDL particles), large HDL-P, and apoC3-lacking HDL-C were significantly associated with lower incidence/progression of AVC. Neither small or medium HDL-P nor apoC3-containing HDL-C was significantly associated with AVC incidence/progression. When included together, a significant association was observed only for HDL-C, but not for HDL-P. Secondary analyses showed an inverse relationship between CETP mass, but not activity, and AVC incidence/progression. In exploratory assessments, inverse associations for HDL-C, HDL-P, large HDL-P, and apoC3-lacking HDL with AVC incidence/progression were more pronounced for older, male, and White participants. ApoC3-containing HDL-C only showed a positive association with AVC in these subgroups. In a multiethnic population, HDL-C, HDL-P, large HDL-P, and apoC3-lacking HDL-C were inversely associated with long-term incidence and progression of AVC. Further investigation of HDL composition and mechanisms could be useful in understanding pathways that slow AVC.

Sections du résumé

BACKGROUND
Aortic valve calcification (AVC) shares pathological features with atherosclerosis. Lipoprotein components have been detected in aortic valve tissue, including HDL (high-density lipoprotein). HDL measures have inverse associations with cardiovascular disease, but relationships with long-term AVC progression are unclear. We investigated associations of HDL cholesterol, HDL-particle number and size, apoC3-defined HDL subtypes, and, secondarily, CETP (cholesteryl ester transfer protein) mass and activity, with long-term incidence and progression of AVC.
METHODS
We used linear mixed-effects models to evaluate the associations of baseline HDL indices with AVC. AVC was quantified by Agatston scoring of up to 3 serial computed tomography scans over a median of 8.9 (maximum 11.2) years of follow-up in the Multi-Ethnic Study of Atherosclerosis (n=6784).
RESULTS
After adjustment, higher concentrations of HDL-C (high-density lipoprotein cholesterol), HDL-P (HDL particles), large HDL-P, and apoC3-lacking HDL-C were significantly associated with lower incidence/progression of AVC. Neither small or medium HDL-P nor apoC3-containing HDL-C was significantly associated with AVC incidence/progression. When included together, a significant association was observed only for HDL-C, but not for HDL-P. Secondary analyses showed an inverse relationship between CETP mass, but not activity, and AVC incidence/progression. In exploratory assessments, inverse associations for HDL-C, HDL-P, large HDL-P, and apoC3-lacking HDL with AVC incidence/progression were more pronounced for older, male, and White participants. ApoC3-containing HDL-C only showed a positive association with AVC in these subgroups.
CONCLUSIONS
In a multiethnic population, HDL-C, HDL-P, large HDL-P, and apoC3-lacking HDL-C were inversely associated with long-term incidence and progression of AVC. Further investigation of HDL composition and mechanisms could be useful in understanding pathways that slow AVC.

Identifiants

pubmed: 35979837
doi: 10.1161/ATVBAHA.122.318004
pmc: PMC9492641
mid: NIHMS1829035
doi:

Substances chimiques

Cholesterol Ester Transfer Proteins 0
Cholesterol, HDL 0
Lipoproteins, HDL 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1272-1282

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL071739
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95160
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001079
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95169
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95164
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95162
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95168
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95165
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95159
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95161
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95167
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000040
Pays : United States
Organisme : NHLBI NIH HHS
ID : K24 HL135413
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95166
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR025005
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95163
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL146982
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002556
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Expert Rev Proteomics. 2018 Jan;15(1):31-40
pubmed: 29113513
Eur Heart J. 2022 Feb 12;43(7):683-697
pubmed: 34849696
J Am Coll Cardiol. 2010 Jun 1;55(22):2491-8
pubmed: 20510217
Circulation. 2018 Mar 27;137(13):1364-1373
pubmed: 29162611
Arterioscler Thromb Vasc Biol. 2016 May;36(5):1003-9
pubmed: 26941019
J Am Heart Assoc. 2015 Aug 06;4(8):e001726
pubmed: 26251281
Circ Res. 2018 Jan 5;122(1):106-112
pubmed: 29018035
J Mol Histol. 2020 Oct;51(5):559-571
pubmed: 32794037
Circulation. 2020 Aug 18;142(7):657-669
pubmed: 32804568
Eur Heart J. 2010 Aug;31(16):2049-57
pubmed: 20304838
Atherosclerosis. 2019 Jun;285:79-86
pubmed: 31048102
Can J Cardiol. 2011 Nov-Dec;27(6):800-8
pubmed: 21742465
Nat Rev Dis Primers. 2016 Mar 03;2:16006
pubmed: 27188578
J Am Heart Assoc. 2016 May 20;5(5):
pubmed: 27207961
Int J Mol Med. 2018 Jan;41(1):61-68
pubmed: 29115584
Eur J Prev Cardiol. 2016 Jan;23(1):41-9
pubmed: 25062744
Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):55-63
pubmed: 24248942
Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):487-499
pubmed: 29371248
JAMA. 2003 Oct 15;290(15):2030-40
pubmed: 14559957
Clin Chem. 2015 May;61(5):714-23
pubmed: 25779987
N Engl J Med. 2013 Feb 7;368(6):503-12
pubmed: 23388002
J Am Coll Cardiol. 2015 Aug 4;66(5):561-77
pubmed: 26227196
Atherosclerosis. 2011 Dec;219(2):538-44
pubmed: 21917259
J Am Heart Assoc. 2018 Mar 14;7(6):
pubmed: 29540426
Circulation. 1968 Jul;38(1 Suppl):61-7
pubmed: 4894151
Br J Pharmacol. 2008 Jun;154(4):765-73
pubmed: 18414386
Clin Chem. 2017 Jan;63(1):288-296
pubmed: 27811210
Front Pharmacol. 2018 Jan 22;8:989
pubmed: 29403378
Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):796-801
pubmed: 20075420
Atherosclerosis. 2016 Aug;251:454-459
pubmed: 27320173
Atherosclerosis. 2008 Oct;200(2):359-67
pubmed: 18243217
J Am Coll Cardiol. 2012 Aug 7;60(6):508-16
pubmed: 22796256
Sci Rep. 2017 May 24;7(1):2312
pubmed: 28539597
Clin Chem. 2016 Jul;62(7):1020-31
pubmed: 27173011
Circulation. 2021 Jun 8;143(23):2293-2309
pubmed: 34097448
Am J Epidemiol. 2002 Nov 1;156(9):871-81
pubmed: 12397006
Atherosclerosis. 2021 Oct;335:126-134
pubmed: 34511241
Arterioscler Thromb Vasc Biol. 2018 Sep;38(9):2236-2244
pubmed: 30026268
Acad Radiol. 2006 Feb;13(2):166-72
pubmed: 16428051
JAMA. 2014 Nov 5;312(17):1764-71
pubmed: 25344734
Sci Rep. 2019 Jul 10;9(1):9996
pubmed: 31292457
Circulation. 2018 Jul 24;138(4):377-393
pubmed: 29588317
J Biol Chem. 2021 Jan-Jun;296:100193
pubmed: 33334888
Heart. 2016 Nov 15;102(22):1826-1834
pubmed: 27411840
Clin Lab Med. 2006 Dec;26(4):847-70
pubmed: 17110242
Arterioscler Thromb Vasc Biol. 2009 Nov;29(11):1975-80
pubmed: 19729614
J Transl Med. 2017 Oct 27;15(1):219
pubmed: 29078787
Arterioscler Thromb Vasc Biol. 2014 Feb;34(2):457-62
pubmed: 24334872
Diabetes. 2009 Apr;58(4):813-9
pubmed: 19136658
Heart. 2021 Sep;107(18):1493-1502
pubmed: 34083406

Auteurs

Anna E Bortnick (AE)

Department of Medicine, Division of Cardiology (A.E.B., C.J.R.), Albert Einstein College of Medicine, Bronx NY.
Division of Geriatrics (A.E.B.), Albert Einstein College of Medicine, Bronx NY.

Petra Buzkova (P)

Department of Biostatistics, University of Washington, Seattle (P.B.).

James D Otvos (JD)

Laboratory Corporation of America Holdings (LabCorp), Morrisville, NC (J.D.O.).

Majken K Jensen (MK)

Department of Nutrition (M.K.J.), Harvard T.H. Chan School of Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Channing Division of Network Medicine, Department of Medicine (M.K.J.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Michael Y Tsai (MY)

Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis (M.Y.T.).

Matthew J Budoff (MJ)

Division of Cardiology, The Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance, CA (M.J.B.).

Rachel H Mackey (RH)

Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, PA (R.H.M., S.R.E.K.).
Premier Applied Sciences, Inc, Charlotte, NC (R.H.M.).

Samar R El Khoudary (SR)

Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, PA (R.H.M., S.R.E.K.).

Elda Favari (E)

Department of Food and Drug, University of Parma, Italy (E.F.).

Ryung S Kim (RS)

Department of Epidemiology and Population Health (R.S.K., C.J.R.), Albert Einstein College of Medicine, Bronx NY.

Carlos J Rodriguez (CJ)

Department of Medicine, Division of Cardiology (A.E.B., C.J.R.), Albert Einstein College of Medicine, Bronx NY.
Department of Epidemiology and Population Health (R.S.K., C.J.R.), Albert Einstein College of Medicine, Bronx NY.

George Thanassoulis (G)

Department of Medicine, Division of Cardiology, McGill University Health Center, Montreal' Canada (G.T.).

Jorge R Kizer (JR)

Cardiology Section, San Francisco VA Health Care System, CA (J.R.K.).
Departments of Medicine, Epidemiology and Biostatistics, University of California' San Francisco (J.R.K.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH